Catheter ablation using pulsed-field energy: Advantages and limitations compared with conventional energy
Kenji Kuroki MD, PhD
Department of Cardiology, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan
Search for more papers by this authorCorresponding Author
Hiroshi Tada MD, PhD
Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan
Correspondence
Hiroshi Tada, Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuokashimoaizuki, Eiheiji, Yoshida District, Fukui 910-1193, Japan.
Email: [email protected]
Search for more papers by this authorKenji Kuroki MD, PhD
Department of Cardiology, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan
Search for more papers by this authorCorresponding Author
Hiroshi Tada MD, PhD
Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan
Correspondence
Hiroshi Tada, Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuokashimoaizuki, Eiheiji, Yoshida District, Fukui 910-1193, Japan.
Email: [email protected]
Search for more papers by this authorAbstract
Atrial fibrillation (AF) poses significant risks of heart failure and stroke, emphasizing effective treatment. Catheter ablation using thermal energy sources, such as radiofrequency or cryoballoon ablation, has shown greater success in maintaining sinus rhythm compared with drug therapy. However, thermal ablation (TA) is associated with serious complications, such as atrial-esophageal fistula, phrenic nerve palsy, and pulmonary vein stenosis. Pulsed-field ablation (PFA) is an emerging ablation energy source that uses electroporation to selectively target cardiac tissue while sparing adjacent structures such as nerves and blood vessels. Two randomized controlled trials have demonstrated that PFA is comparable to TA in both efficacy and safety at a 1-year follow-up and had shorter procedure times. A review of six meta-analyses consistently showed shorter procedural times for PFA across all studies. Additionally, three out of the four recent studies with large samples reported lower recurrence rates with PFA. Regarding complication rates, four out of four studies showed lower incidences of phrenic nerve injury with PFA, and two out of three studies reported lower rates of esophageal injury with PFA. However, four out of four studies indicated higher incidences of cardiac tamponade with PFA, highlighting the need for caution among early-career operators. Furthermore, careful monitoring is required considering the possible unforeseen complications specific to PFA and the lack of long-term follow-up data. Despite these concerns, PFA shows promise as a safer, more effective, and efficient alternative to TA for AF, particularly as operator experience and device technology continue to advance.
CONFLICT OF INTEREST STATEMENT
Dr. Kenji Kuroki received grants from Medtronic Co., Ltd. and Abbott Medical Japan LLC. Dr. Kuroki is a consultant for Abbott Medical Japan LLC, Microport CRM Japan Co., Ltd., and Kaneka Corporation. Dr. Hiroshi Tada received honoraria for lectures or speakers bureaus from Daiichi Sankyo Company, Ltd., Novartis Pharma K.K., Medtronic Japan Co., Ltd., Biotronik Japan, Inc., Bristol Myers Squibb, and Boston-Scientific Japan K.K. Dr. Tada also received grants (Investigator-initiated study unrelated to the manuscript topic) from Abbott Medical Japan LLC, Daiichi Sankyo Company, Ltd., Nippon Boehringer Ingelheim Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., and Marubun Tsusyo K.K.
REFERENCES
- 1Akao M, Inoue H, Yamashita T, Atarashi H, Ikeda T, Koretsune Y, et al. Relationship between direct oral anticoagulant doses and clinical outcomes in elderly patients with non-valvular atrial fibrillation―ANAFIE registry sub-analysis. Circ J. 2023; 87(12): 1765–1774.
- 2Chao TF, Potpara TS, Lip GYH. Atrial fibrillation: stroke prevention. Lancet Reg Health Eur. 2024; 37:100797.
- 3Geng M, Lin A, Nguyen TP. Revisiting antiarrhythmic drug therapy for atrial fibrillation: reviewing lessons learned and redefining therapeutic paradigms. Front Pharmacol. 2020; 11(11):581837. https://doi.org/10.3389/fphar.2020.581837
- 4Hakalahti A, Biancari F, Nielsen JC, Raatikainen MJ. Radiofrequency ablation vs. antiarrhythmic drug therapy as first-line treatment of symptomatic atrial fibrillation: systematic review and meta-analysis. Europace. 2015; 17(3): 370–378.
- 5Kheiri B, Simpson TF, Przybylowicz R, Merrill M, Alhamoud H, Osman M, et al. Ablation versus antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation: a meta-analysis of randomized trials. Circ Arrhythm Electrophysiol. 2021; 14(8):e009692.
- 6Chen Y-H, Lu Z-Y, Xiang Y, Hou J-W, Wang Q, Lin H, et al. Cryoablation vs. radiofrequency ablation for treatment of paroxysmal atrial fibrillation: a systematic review and meta-analysis. EP Europace. 2017; 19(5): 784–794.
- 7Yamasaki H, Nakahara S, Sohara H, Yoshida Y, Kohno T, Shimane A, et al. HotBalloon pulmonary vein isolation registry study―real-world efficacy and safety of HotBalloon ablation. Circ J. 2022; 87(1): 65–73.
- 8My I, Bordignon S, Butt M, Rottner L, Marc L, Moser F, et al. Novel radiofrequency balloon catheter―impact of ablation parameters on single-shot isolation. Circ J. 2023; 87(7): 950–956.
- 9Schmidt M, Dorwarth U, Andresen D, Brachmann J, Kuck K, Kuniss M, et al. German ablation registry: cryoballoon vs. radiofrequency ablation in paroxysmal atrial fibrillation-one-year outcome data. Heart Rhythm. 2016; 13(4): 836–844.
- 10Song W, Lv T, Zhang N, Li G, Tse G, Liu T. Long-term efficacy and safety of cryoballoon ablation of atrial fibrillation: a systematic review and meta-analysis. Pacing Clin Electrophysiol. 2024; 47(1): 49–57.
- 11Ye W, Chen Q, Fan G, Zhou X, Wang X, Mao W, et al. Efficacy and safety of visually guided laser balloon versus cryoballoon ablation for paroxysmal atrial fibrillation: a systematic review and meta-analysis. Front Cardiovasc Med. 2023; 10: 10.
- 12Chun JKR, Bordignon S, Last J, Mayer L, Tohoku S, Zanchi S, et al. Cryoballoon versus laserballoon. Circ Arrhythm Electrophysiol. 2021; 14(2):e009294.
- 13Benali K, Khairy P, Hammache N, Petzl A, Da Costa A, Verma A, et al. Procedure-related complications of catheter ablation for atrial fibrillation. J Am Coll Cardiol. 2023; 81(21): 2089–2099.
- 14Della Rocca DG, Magnocavallo M, Natale VN, Gianni C, Mohanty S, Trivedi C, et al. Clinical presentation, diagnosis, and treatment of atrioesophageal fistula resulting from atrial fibrillation ablation. J Cardiovasc Electrophysiol. 2021; 32(9): 2441–2450.
- 15Tanaka Y, Kuroki K, Kaga S. Life-threatening left atrioesophageal fistula complicated with catheter ablation for atrial fibrillation in a patient with aortic stent graft. Eur Heart J. 2023; 44(44): 4723.
- 16Tachibana S, Okishige K, Sudo K, Shigeta T, Sagawa Y, Nakamura R, et al. Predictors of phrenic nerve injury during pulmonary vein isolation for curing atrial fibrillation with balloon-based visually guided laser ablation. Circ J. 2021; 85(3): 275–282.
- 17Mol D, Renskers L, Balt JC, Bhagwandien RE, Blaauw Y, Van Driel VJHM, et al. Persistent phrenic nerve palsy after atrial fibrillation ablation: follow-up data from The Netherlands Heart Registration. J Cardiovasc Electrophysiol. 2022; 33(3): 559–564.
- 18Ogawa T, Yamashita S, Oseto H, Yokoyama M, Itakura R, Kang R, et al. Pulmonary vein angioplasty for pulmonary vein stenosis after ablation therapy for atrial fibrillation―a report of 7 cases. Circ J. 2022; 86(8): 1229–1236.
- 19Tokuda M, Yamashita S, Shiomi S, Sakurai R, Sato H, Oseto H, et al. Pulmonary vein stenosis after catheter ablation of atrial fibrillation using a cryoballoon, hot balloon, or laser balloon. Circ J. 2023; 87(12): 1711–1719.
- 20Yokoi K, Katsuki T, Yamaguchi T, Otsubo T, Soga Y, Hiroshima K, et al. Pulmonary vein intervention for severe pulmonary vein stenosis after atrial fibrillation ablation―a retrospective cohort study. Circ J. 2024; 88(7): 1099–1106.
- 21Kitai T, Kasai Y, Kasai J, Morita J, Fujita T. Mediastinal hematoma associated with radiofrequency catheter ablation of atrial fibrillation. Circ J. 2022; 86(12): 2041.
- 22Kasai Y, Kasai J, Kitai T, Morita J, Fujita T. Iatrogenic left ventricular pseudoaneurysm after successful radiofrequency catheter ablation for premature ventricular contraction originating from the posterior papillary muscles. Circ J. 2023; 87(3): 464.
- 23Verma A, Haines DE, Boersma LV, Sood N, Natale A, Marchlinski FE, et al. Pulsed field ablation for the treatment of atrial fibrillation: pulsed AF pivotal trial. Circulation. 2023; 147(19): 1422–1432.
- 24Maor E, Sugrue A, Witt C, Vaidya VR, DeSimone CV, Asirvatham SJ, et al. Pulsed electric fields for cardiac ablation and beyond: a state-of-the-art review. Heart Rhythm. 2019; 16(7): 1112–1120.
- 25Koruth JS, Kuroki K, Kawamura I, Brose R, Viswanathan R, Buck ED, et al. Pulsed field ablation versus radiofrequency ablation: esophageal injury in a novel porcine model. Circ Arrhythm Electrophysiol. 2020; 13(3):e008303.
- 26Van Driel VJHM, Neven K, Van Wessel H, Vink A, Doevendans PAFM, Wittkampf FHM. Low vulnerability of the right phrenic nerve to electroporation ablation. Heart Rhythm. 2015; 12(8): 1838–1844.
- 27Howard B, Haines DE, Verma A, Kirchhof N, Barka N, Onal B, et al. Characterization of phrenic nerve response to pulsed field ablation. Circ Arrhythm Electrophysiol. 2022; 15(6):e010127.
- 28Ota C, Yamasaki H, Nogami A, Ieda M. Silent cardiac perforation during visually guided laser balloon ablation. Circ J. 2022; 86(10): 1587.
- 29Viles-Gonzalez JF, Berjano E, d'Avila A. Complications of radiofrequency catheter ablation: can we prevent steam pops? JACC Clin Electrophysiol. 2018; 4(4): 501–503.
- 30Mori H, Kato R, Sumitomo N, Ikeda Y, Goto K, Tanaka S, et al. Relationship between the ablation index, lesion formation, and incidence of steam pops. J Arrhythm. 2019; 35(4): 636–644.
- 31Van Driel VJHM, Neven KGEJ, Van Wessel H, Du Pré BC, Vink A, Doevendans PAFM, et al. Pulmonary vein stenosis after catheter ablation. Circ Arrhythm Electrophysiol. 2014; 7(4): 734–738.
- 32Kuroki K, Whang W, Eggert C, Lam J, Leavitt J, Kawamura I, et al. Ostial dimensional changes after pulmonary vein isolation: pulsed field ablation vs radiofrequency ablation. Heart Rhythm. 2020; 17(9): 1528–1535.
- 33Koruth JS, Kuroki K, Kawamura I, Stoffregen WC, Dukkipati SR, Neuzil P, et al. Focal pulsed field ablation for pulmonary vein isolation and linear atrial lesions. Circ Arrhythm Electrophysiol. 2020; 13(6):e008716.
- 34Reddy VY, Anter E, Rackauskas G, Peichl P, Koruth JS, Petru J, et al. Lattice-tip focal ablation catheter that toggles between radiofrequency and pulsed field energy to treat atrial fibrillation: a first-in-human trial. Circ Arrhythm Electrophysiol. 2020; 13(6):e008718.
- 35Howard B, Verma A, Tzou WS, Mattison L, Kos B, Miklavčič D, et al. Effects of electrode-tissue proximity on cardiac lesion formation using pulsed field ablation. Circ Arrhythm Electrophysiol. 2022; 15(10):e011110.
- 36Mattison L, Verma A, Tarakji KG, Reichlin T, Hindricks G, Sack KL, et al. Effect of contact force on pulsed field ablation lesions in porcine cardiac tissue. J Cardiovasc Electrophysiol. 2023; 34: 693–699.
- 37Reddy VY, Dukkipati SR, Neuzil P, Anic A, Petru J, Funasako M, et al. Pulsed field ablation of paroxysmal atrial fibrillation: 1-year outcomes of IMPULSE, PEFCAT, and PEFCAT II. JACC Clin Electrophysiol. 2021; 7(5): 614–627.
- 38Nakagawa H, Castellvi Q, Neal R, Girouard S, Laughner J, Ikeda A, et al. Effects of contact force on lesion size during pulsed field catheter ablation: histochemical characterization of ventricular lesion boundaries. Circ Arrhythm Electrophysiol. 2024; 17(1):e012026.
- 39Duytschaever M, De Potter T, Grimaldi M, Anic A, Vijgen J, Neuzil P, et al. Paroxysmal atrial fibrillation ablation using a novel variable-loop biphasic pulsed field ablation catheter integrated with a 3-dimensional mapping system: 1-year outcomes of the multicenter inspIRE study. Circ Arrhythm Electrophysiol. 2023; 16(3):e011780.
- 40Schmidt B, Bordignon S, Tohoku S, Chen S, Bologna F, Urbanek L, et al. 5S study: safe and simple single shot pulmonary vein isolation with pulsed field ablation using sedation. Circ Arrhythm Electrophysiol. 2022; 15(6):e010817.
- 41Reddy VY, Peichl P, Anter E, Rackauskas G, Petru J, Funasako M, et al. A focal ablation catheter toggling between radiofrequency and pulsed field energy to treat atrial fibrillation. JACC Clin Electrophysiol. 2023; 9(8 Pt 3): 1786–1801.
- 42Reddy VY, Anter E, Peichl P, Rackauskas G, Petru J, Funasako M, et al. First-in-human clinical series of a novel conformable large-lattice pulsed field ablation catheter for pulmonary vein isolation. Europace. 2024; 26(4):euae090.
- 43Sanders P, Healy S, Emami M, Kotschet E, Miller A, Kalman JM. Initial clinical experience with the balloon-in-basket pulsed field ablation system: acute results of the VOLT CE mark feasibility study. Europace. 2024; 26(5):euae118.
- 44Reddy VY, Gerstenfeld EP, Natale A, Whang W, Cuoco FA, Patel C, et al. Pulsed field or conventional thermal ablation for paroxysmal atrial fibrillation. N Engl J Med. 2023; 389: 1660–1671.
- 45Anter E, Mansour M, Nair DG, Sharma D, Taigen TL, Neuzil P, et al. Dual-energy lattice-tip ablation system for persistent atrial fibrillation: a randomized trial. Nat Med. 2024; 30: 2303–2310.
- 46Osmancik P, Bacova B, Hozman M, Pistkova J, Kunstatova V, Sochorova V, et al. Myocardial damage, inflammation, coagulation, and platelet activity during catheter ablation using radiofrequency and pulsed-field energy. JACC Clin Electrophysiol. 2024; 10(3): 463–474.
- 47Aldaas OM, Malladi C, Han FT, Hoffmayer KS, Krummen D, Ho G, et al. Pulsed field ablation versus thermal energy ablation for atrial fibrillation: a systematic review and meta-analysis of procedural efficiency, safety, and efficacy. J Interv Card Electrophysiol. 2023; 67(3): 639–648.
- 48Zhang H, Zhang H, Lu H, Mao Y, Chen J. Meta-analysis of pulsed-field ablation versus cryoablation for atrial fibrillation. Pacing Clin Electrophysiol. 2024; 47(5): 603–613.
- 49de Campos M, Moraes VRY, Daher RF, Micheleto JPC, de Campos LAV, Barros GFA, et al. Pulsed-field ablation versus thermal ablation for atrial fibrillation: a meta-analysis. Heart Rhythm O2. 2024; 5(6): 385–395.
- 50Rudolph I, Mastella G, Bernlochner I, Steger A, Von Olshausen G, Hahn F, et al. Efficacy and safety of pulsed field ablation compared to cryoballoon ablation in the treatment of atrial fibrillation: a meta-analysis. Eur Heart J Open. 2024; 4(3):oeae044.
- 51Amin AM, Nazir A, Abuelazm MT, Ibrahim AA, Elbenawi H, Aboutaleb A, et al. Efficacy and safety of pulsed- field versus conventional thermal ablation for atrial fibrillation: a systematic review and meta- analysis. J Arrhythm. 2024; 40: 1059–1074.
- 52Iqbal M, Kamarullah W, Pranata R, Putra ICS, Karwiky G, Achmad C, et al. Meta-analysis of pulsed field ablation versus thermal ablation for pulmonary vein isolation in AF: a broad overview focusing on efficacy, safety and outcomes. Arrhythm Electrophysiol Rev. 2024; 13:e13.
- 53Turagam MK, Neuzil P, Schmidt B, Reichlin T, Neven K, Metzner A, et al. Safety and effectiveness of pulsed field ablation to treat atrial fibrillation: one-year outcomes from the MANIFEST-PF registry. Circulation. 2023; 148(1): 35–46.
- 54Ekanem E, Neuzil P, Reichlin T, Kautzner J, Van Der Voort P, Jais P, et al. Safety of pulsed field ablation in more than 17,000 patients with atrial fibrillation in the MANIFEST-17K study. Nat Med. 2024; 30(7): 2020–2029.
- 55Tilz RR, Vogler J, Kirstein B, Eitel C, Phan H-L, Popescu SȘ, et al. Pulsed field ablation-based pulmonary vein isolation using a simplified single-access single-catheter approach―the fast and furious PFA study. Circ J. 2023; 87(12): 1722–1726.
- 56Tsai T-Y, Lo L-W, Cheng W-H, Liu S-H, Lin Y-J, Chang S-L, et al. 10-Year outcomes of patients with non-paroxysmal atrial fibrillation undergoing catheter ablation. Circ J. 2022; 87(1): 84–91.
- 57Nogami A, Soejima K, Morishima I, Hiroshima K, Kato R, Sakagami S, et al. Real-world investigation on anticoagulation management before and after catheter ablation for atrial fibrillation in Japan―periprocedural and long-term outcomes. Circ J. 2022; 87(1): 50–62.
- 58Matsunaga-Lee Y, Inoue K, Tanaka N, Masuda M, Watanabe T, Makino N, et al. Appropriate selection of substrate ablation for persistent atrial fibrillation using Intraprocedural assessment. Circ J. 2024; 88(7): 1068–1077.
- 59Sato T, Sotomi Y, Hikoso S, Nakatani D, Mizuno H, Okada K, et al. Sex differences in the efficacy of pulmonary vein isolation alone vs. extensive catheter ablation in patients with persistent atrial fibrillation. Circ J. 2022; 86(8): 1207–1216.
- 60Miyazaki S. Optimal ablation strategy for non-paroxysmal atrial fibrillation during the index procedure. Circ J. 2024; 88(7): 1078–1080.
- 61Wu S-J, Lo L-W, Chung F-P, Lin Y-J, Chang S-L, Hu Y-F, et al. Comparison of long-term clinical outcomes between segmental and circumferential pulmonary vein isolation in patients undergoing repeat atrial fibrillation ablation. Circ J. 2023; 87(12): 1750–1756.
- 62Kueffer T, Tanner H, Madaffari A, Seiler J, Haeberlin A, Maurhofer J, et al. Posterior wall ablation by pulsed-field ablation: procedural safety, efficacy, and findings on redo procedures. Europace. 2023; 26(1):euae006.
- 63Turagam MK, Neuzil P, Schmidt B, Reichlin T, Neven K, Metzner A, et al. Impact of left atrial posterior wall ablation during pulsed-field ablation for persistent atrial fibrillation. JACC Clin Electrophysiol. 2024; 10(5): 900–912.
- 64Koruth J, Kuroki K, Iwasawa J, Enomoto Y, Viswanathan R, Brose R, et al. Preclinical evaluation of pulsed field ablation. Circ Arrhythm Electrophysiol. 2019; 12(12):e007781.
- 65Ollitrault P, Chaumont C, Font J, Manninger M, Conti S, Matusik PT, et al. Superior vena cava isolation using a pentaspline pulsed-field ablation catheter: feasibility and safety in patients undergoing atrial fibrillation catheter ablation. Europace. 2024; 26(7):euae160.
- 66Di Biase L, Marazzato J, Govari A, Altman A, Beeckler C, Keyes J, et al. Pulsed field ablation index-guided ablation for lesion formation: impact of contact force and number of applications in the ventricular model. Circ Arrhythm Electrophysiol. 2024; 17(4):e012717.
- 67Iwakawa H, Takigawa M, Yamaguchi J, Martin CA, Goya M, Yamamoto T, et al. Superiority of the combination of input and output parameters to the single parameter for lesion size estimation. Circ J. 2023; 87(12): 1757–1764.
- 68Chieng D, Segan L, Sugumar H, Al-Kaisey A, Hawson J, Moore BM, et al. Higher power short duration vs. lower power longer duration posterior wall ablation for atrial fibrillation and oesophageal injury outcomes: a prospective multi-centre randomized controlled study (hi-Lo HEAT trial). EP Europace. 2023; 25(2): 417–424.
- 69Tsuda T, Kato T, Usuda K, Kusayama T, Usui S, Sakata K, et al. Effect of catheter ablation for atrial fibrillation in heart failure with mid-range or preserved ejection fraction―pooled analysis of the AF frontier ablation registry and Hokuriku-plus AF registry. Circ J. 2023; 87(7): 939–946.
- 70Kondo H, Takahashi N. Catheter ablation for atrial fibrillation could be a promising therapeutic option in patients with heart failure with mid-range or preserved ejection fraction. Circ J. 2023; 87(7): 947–949.
- 71Kawaji T, Shizuta S, Aizawa T, Nishiwaki S, Yoshizawa T, Nishiuchi S, et al. Prognostic importance of B-type natriuretic peptide level in patients undergoing catheter ablation for atrial fibrillation. Circ J. 2023; 87(12): 1730–1739.
- 72Onishi N, Kaitani K, Nakagawa Y, Kobori A, Inoue K, Kurotobi T, et al. Radiofrequency catheter ablation for atrial fibrillation patients on hemodialysis (from the Kansai plus atrial fibrillation registry)―clinical impact of early recurrence. Circ J. 2024; 88(7): 1057–1064.
- 73Kimura M. Challenges of catheter ablation for atrial fibrillation in hemodialysis patients. Circ J. 2024; 88(7): 1065–1067.
- 74Iwakoshi H, Asada YC, Nakata M, Makino M, Munakata J, Tomura N, et al. Impact of sleep apnea on nocturnal parasympathetic activity in atrial fibrillation patients after catheter ablation―implications for heart rate variability analysis. Circ J. 2024; 88(7): 1081–1088.
- 75Wang Z, Li J, Chen J, Guo H, He H, Jiao S, et al. Relationship between Epicardial adipose tissue volume and recurrence after ablation in premature ventricular complexes. Circ J. 2024; 88(7): 1047–1054.
- 76Kuo L, Wang G-J, Chang S-L, Lin Y-J, Chung F-P, Lo L-W, et al. Feasibility of auto-quantified epicardial adipose tissue in predicting atrial fibrillation recurrence after catheter ablation. Circ J. 2024; 88(7): 1089–1098.
- 77Sakai J, Takami M, Fukuzawa K, Kiuchi K, Nakamura T, Yatomi A, et al. Sex differences in the regional analysis of nonpulmonary vein foci and epicardial adipose tissue in patients with atrial fibrillation. Circ J. 2022; 87(1): 29–40.
- 78Minami K, Kazawa M, Kakuta T, Fukushima S, Fujita T, Kabata D, et al. Early atrial tachyarrhythmia recurrence predicts late atrial tachyarrhythmia recurrence after the cryo-maze procedure―an observational study. Circ J. 2022; 87(1): 76–83.
- 79Chikata A, Kato T, Usuda K, Takamura M. Fractionated potential-guided slow pathway ablation for slow-fast atrioventricular nodal reentrant tachycardia in a patient with persistent left superior vena cava using ultra-high-density mapping. Circ J. 2023; 87(7): 1037.
- 80Nakasone K, Nishimori M, Kiuchi K, Shinohara M, Fukuzawa K, Takami M, et al. Development of a visualization deep learning model for classifying origins of ventricular arrhythmias. Circ J. 2022; 86(8): 1273–1280.
- 81Nyuta E, Takemoto M, Sakai T, Antoku Y, Mito T, Umemoto S, et al. Epicardial connections after a conventional pulmonary vein antrum isolation in patients with atrial fibrillation. Circ J. 2022; 86(8): 1219–1228.
- 82Hasebe H, Yoshida K, Nogami A, Furuyashiki Y, Ieda M. Impact of interatrial epicardial connections on the dominant frequency of atrial fibrillation. Circ J. 2023; 87(7): 973–981.
- 83Kim J, Bak M, Park S-J, Jeong DS, Chung S, Kim D, et al. Clinical implication of left atrial appendage emptying velocity in thoracoscopic ablation of atrial fibrillation. Circ J. 2023; 87(12): 1742–1749.
- 84Kataoka N, Imamura T. How to assess the impact of left atrial appendage emptying velocity on the recurrence of atrial fibrillation after catheter ablation. Circ J. 2024; 88(5): 843.
- 85Reddy VY, Petru J, Funasako M, Kopriva K, Hala P, Chovanec M, et al. Coronary arterial spasm during pulsed field ablation to treat atrial fibrillation. Circulation. 2022; 146(24): 1808–1819.
- 86Popa MA, Venier S, Menè R, Della Rocca D, Sacher F, Derval N, et al. Characterization and clinical significance of hemolysis after pulsed field ablation for atrial fibrillation: results of a multicenter analysis. Circ Arrhythm Electrophysiol. 2024; 17(10):e012732. https://doi.org/10.1161/CIRCEP.124.012732
- 87Nies M, Koruth JS, Mlček M, Watanabe K, Tibenská VC, Královec Š, et al. Hemolysis after pulsed field ablation: impact of lesion number and catheter-tissue contact. Circ Arrhythm Electrophysiol. 2024; 17(6):e012765.